fenofibrate has been researched along with fenofibric acid in 217 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (23.04) | 18.7374 |
| 1990's | 24 (11.06) | 18.2507 |
| 2000's | 52 (23.96) | 29.6817 |
| 2010's | 85 (39.17) | 24.3611 |
| 2020's | 6 (2.76) | 2.80 |
| Authors | Studies |
|---|---|
| Barr, RJ; Bean, JS; Bensch, WR; Dominianni, SJ; Huang, N; Kauffman, RF; Luffer-Atlas, D; Maise, DE; Mantlo, NB; Mayhugh, D; Montrose-Rafizadeh, C; Osborne, J; Rungta, D; Saeed, A; Singh, J; Thompson, RC; Wang, X; Xu, Y; Yumibe, NP; Zink, RW | 1 |
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Aoki, T; Asaki, T; Hamamoto, T; Kuwabara, K; Murakami, K; Ohmachi, S; Sugiyama, Y; Todo, M | 1 |
| Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T | 1 |
| Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J | 1 |
| Atshaves, BP; Gupta, S; Huang, H; Kier, AB; Landrock, D; Landrock, KK; Martin, GG; McIntosh, AL; Schroeder, F | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Aarsland, A; Berge, RK | 1 |
| Galteau, MM; Guéguen, R; Leroy, P; Liu, HF; Magdalou, J; Nicolas, A; Siest, G; Vincent-Viry, M | 1 |
| Fournel, S; Magdalou, J; Pinon, P; Siest, G | 1 |
| Adrien, A; Lacour, JP; Ortonne, JP | 1 |
| Bard, JM; Douste-Blazy, P; Fievet, C; Fruchart, JC; Kandoussi, A; Slimane, M | 1 |
| Balestreri, R; Bertolini, S; Carozzi, A; Cotta Ramusino, AM; Daga, A; Degl'Innocenti, ML; Elicio, N; Fusi, MG | 1 |
| Desager, JP; Harvengt, C; Heller, FR | 1 |
| Sermukslis, B; Smud, R | 1 |
| Beaumont, JL; Beaumont, V; Buxtorf, JC; Carcone, B; Doucet, F; Edouard, L; Jacotot, B | 1 |
| Laredo, C; Torossian, F | 1 |
| Carozzi, A; Ramusino, AC | 1 |
| Jacob, B; Merk, W; Schwandt, P; Weisweiler, P | 1 |
| Furet, Y; Massen, H | 1 |
| Leiss, O; Meyer-Krahmer, K; von Bergmann, K | 1 |
| Acuña, AM; Gladstein, J; Tesone, PA | 1 |
| Delcroix, C; Malmendier, CL | 1 |
| Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J | 1 |
| Podda, M; Zuin, M | 1 |
| Ditschuneit, H; Ditschuneit, HH; Schneider, A; Stange, EF | 1 |
| Drouin, P; Morin, C; Panek, E; Siest, G; Steinmetz, J | 1 |
| Chicaud, P; Debry, G; Demange, J; Drouin, P | 2 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Santafé Oroz, J; Segarra Domènech, J | 1 |
| Sznajderman, M | 1 |
| Häring, HU; Mehnert, H; Renner, R; Schleicher, E | 1 |
| Leiss, O; von Bergmann, K | 1 |
| Bonfiglioli, D; Fasoli, A; Ottomano, C; Pogliaghi, I; Sommariva, D | 1 |
| Harvengt, C; Heller, F; Pourbaix, S | 1 |
| Bonfiglioli, D; Cabrini, E; Fasoli, A; Pogliaghi, I; Sommariva, D | 1 |
| Harvengt, C; Heller, F | 1 |
| Hitz, J; Siest, G; Steinmetz, J | 1 |
| Debeer, LJ; Declercq, PE; Mannaerts, GP; Van Veldhoven, P | 1 |
| Barrat, E; Debry, G; Drouin, P; Gariot, P; Pointel, JP | 1 |
| Blane, GF; Blümcke, S; Edmondson, NA; Lobeck, H; Prentice, DE; Schwartzkopff, W | 1 |
| Avogaro, P; Belussi, F; Bittolo Bon, G; Cazzolato, G; Pontoglio, E | 1 |
| Barrat, E; Debry, G; Drouin, P; Gariot, P; Mejean, L; Pointel, JP | 1 |
| Chazan, JB; Majoie, B; Pascal, M; Sepulchre, C | 1 |
| Aldini, R; Barbara, L; Benelli, A; Borzatta, V; Geminiani, S; Mascellani, G; Morselli, A; Roda, A; Roda, E | 1 |
| Desager, JP; Harvengt, C; Heller, F | 2 |
| Daubresse, JC | 1 |
| Albaigés, J; Caturla, MC | 1 |
| Cassou, M; Giraud, P; Guidet, M; Paul, R | 1 |
| Bortolini, U; Fasoli, A; Massaroli, C; Paolino, C; Sommariva, D | 1 |
| Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K | 1 |
| Costermans, J; Desager, JP; Harvengt, C; Verberckmoes, R | 1 |
| Alsasua, MT; Cepeda, L; Gómez, MP | 1 |
| Lehtonen, A; Viikari, J | 1 |
| Chessebeuf, M; Dulery, B; Hammami, M; Legendre, M; Maume, BF; Noly, P; Padieu, P | 1 |
| Lutz, WK; Schlatter, C; von Däniken, A | 1 |
| Baron, C; Boissard, G; Legendre, C; Wulfert, E | 1 |
| Ishigami, M; Loo, Y; Sano, K; Sasaki, M; Shin, M; Umezawa, C; Yamashita, Y | 1 |
| Cornu-Chagnon, MC; Dupont, H; Edgar, A | 1 |
| Cossy, C; Galteau, MM; Gueguen, R; Leroy, P; Magdalou, J; Nicolas, A; Siest, G; Vincent-Viry, M | 1 |
| Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J | 1 |
| Bovard-Houppermans, S; Fruchart, JC; Ochoa, A; Zakin, MM | 1 |
| Caldwell, J; Grubb, N; Weil, A | 1 |
| Walsh, KB; Wang, C | 1 |
| Auwerx, J; Briggs, M; Deeb, S; Heyman, RA; Lefebvre, AM; Peinado-Onsurbe, J; Schoonjans, K; Staels, B | 1 |
| Cuniberti, LA; Masnatta, LD; Rey, RH; Werba, JP | 1 |
| Goichot, B; Grunenberger, F; Pradignac, A; Schlienger, JL | 1 |
| Dubovská, D; Mongiellová, V; Raslová, K; Trnovec, T | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| Castell, JV; Gómez-Lechón, MJ; Guillén, I; Miranda, MA; Terencio, MC | 1 |
| Bonnelye, E; Chopin-Delannoy, S; Fruchart, JC; Gervois, P; Laudet, V; Martin, G; Staels, B; Vu-Dac, N | 1 |
| Abe, S; Hayashi, T; Mogi, M; Ono, K | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Andersson, Y; Fruchart, JC; Kosykh, V; Lefebvre, AM; Majd, Z; Martin, G; Najib, J; Sechkin, AV; Staels, B | 1 |
| Chopin-Delannoy, S; Dubois, G; Fadel, A; Fruchart, JC; Gervois, P; Kosykh, V; Laudet, V; Najïb, J; Staels, B | 1 |
| Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Barba, G; Bono, F; Bréchot, C; Demaugre, F; Kohara, K; Kohara, M; Matsuura, Y; Miyamura, T; Perlemuter, G; Sabile, A | 1 |
| Guay, DR | 1 |
| Achari, R; Gustavson, LE; Gutterman, C; Pan, WJ; Rieser, MJ; Wallin, BA; Ye, X | 1 |
| Ceccato, A; Hubert, P; Streel, B | 1 |
| Bilder, G; Byan, L; Minnich, A; Tian, N | 1 |
| Chinetti, G; Corseaux, D; Duriez, P; Fruchart, JC; Jude, B; Neve, BP; Staels, B; Zawadzki, C | 1 |
| Berezowski, V; Blanquart, C; Duez, H; Fruchart, JC; Glineur, C; Martin, G; Najib-Fruchart, J; Poulain, P; Staels, B | 1 |
| Chouini-Lalanne, N; Lhiaubet, V; Paillous, N | 1 |
| Boscá, F; Cosa, G; Miranda, MA; Purohit, S; Scaiano, JC | 1 |
| Fujii, S; Furumoto, T; Goto, D; Ishimori, N; Kaneko, T; Kitabatake, A; Matsumoto, A; Sobel, BE; Sugawara, T; Watano, K | 1 |
| Dane, AL; Martin, PD; Schneck, DW; Warwick, MJ | 1 |
| Higuchi, S; Ichikawa, K; Iida, M; Iino, K; Iwase, M; Ohdo, S; Sonoki, K; Yoshinari, M | 1 |
| Burhenne, J; Ehrhardt, M; Haefeli, WE; Lindenmaier, H; Weiss, J | 1 |
| Mikhailidis, DP; Wierzbicki, AS; Wray, R | 1 |
| Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T | 1 |
| Shihabi, ZK | 1 |
| Ikeda, M; Kakei, M; Matsumoto, S; Mori, M; Okada, S; Shimizu, H; Shimomura, K | 1 |
| Belmadoui, N; Climent, MJ; Encinas, S; Gil, S; Miranda, MA | 1 |
| Auwerx, J; Calmus, Y; Canva, V; Cheng, Y; Conti, F; Desreumaux, P; Dharancy, S; Dubuquoy, L; Gambiez, L; Malapel, M; Mathurin, P; Paris, JC; Perlemuter, G; Philippe, D; Podevin, P; Pol, S; Roskams, T; Schoonjans, K | 1 |
| Balendiran, GK; Haq, W; Rath, NP | 1 |
| Arakawa, R; Nishimaki-Mogami, T; Tamehiro, N; Ueda, K; Yokoyama, S | 1 |
| Kallem, RR; Mullangi, R; Srinivas, NR; Trivedi, RK | 1 |
| Buechler, C; Kirchner, S; Laberer, S; Neumeier, M; Schäffler, A; Schölmerich, J; Weigert, J; Weiss, T | 1 |
| Boulanger, B; Ceccato, A; Chiap, P; Crommen, J; Dewe, W; Govaerts, B; Hubert, P; Mertens, B; Rozet, E; Streel, B | 1 |
| Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD | 1 |
| Kim, CJ | 1 |
| Calignano, A; Farthing, J; Fu, J; Hohmann, A; La Rana, G; LoVerme, J; Mattace-Raso, G; Meli, R; Piomelli, D; Russo, R | 1 |
| Aslanidis, C; Bollheimer, C; Buechler, C; Büttner, R; Neumeier, M; Schäffler, A; Schmidl, C; Schölmerich, J; Weigert, J; Weiss, TS | 1 |
| Burkhardt, RT; Fisher, JE; Straka, RJ | 1 |
| Bauman, JN; Davis, JA; Goosen, TC; Hurst, SI; Loi, CM; Williams, JA; Yu, C | 1 |
| Ide, T; Kobayashi, N; Murakami, K; Nagasawa, M; Tsunoda, M; Utsumi, M | 1 |
| Cariou, B; Costet, P; Jarnoux, AL; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Nguyen, P; Ouguerram, K; Zaïr, Y | 1 |
| Cahay, B; Klinkenberg, R; Mertens, B; Streel, B | 1 |
| Aggerbeck, M; Andersson, U; Cotgreave, I; Ehrenborg, E; Glinghammar, B; Hellmold, H; Norjavaara, E; Rafter, I; Stockling, K; Thulin, P; Tomkiewicz, C | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Filippatos, T; Milionis, HJ | 1 |
| Awni, WM; Chira, TO; Hosmane, B; Kelly, MT; Pradhan, RS; Sleep, DJ; Stolzenbach, JC; Wan, K; Zhu, T | 1 |
| Buttler, SM; Davidson, MH; Jones, PH; Kashyap, ML; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Horne, J; Lim, ML; Porter, CJ; Scanlon, MJ; Simpson, JS; Velkov, T | 1 |
| Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Bhavesh, D; Shah, S | 1 |
| Berezowski, V; Bordet, R; Cecchelli, R; Culot, M; Dehouck, L; Derudas, B; Fenart, L; Mysiorek, C; Staels, B | 1 |
| Jacobson, TA | 1 |
| Benoit-Biancamano, MO; Caron, P; Court, MH; Guillemette, C; Straka, RJ; Tojcic, J | 1 |
| Headey, SJ; Rimmer, KA; Velkov, T | 1 |
| Keating, GM; Yang, LP | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Angus, E; Fincher, S; Garg, R | 1 |
| Adeghate, E; Kalasz, H; Teke, K; Veress, G | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Ansquer, JC; Kelly, MT; Pradhan, RS; Sleep, DJ; Zhu, T | 1 |
| Buist-Homan, M; Deelman, LE; Enrich, C; Faber, KN; Geuken, M; Henning, RH; Hoekstra, M; Moshage, H; Rembacz, KP; van den Heuvel, FA; Woudenberg, J; Woudenberg-Vrenken, TE | 1 |
| Hilleman, DE; Maciejewski, SR; Mohiuddin, SM; Schima, SM; Williams, MA | 1 |
| Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM | 1 |
| García-Calvo, E; Gonzalo, MS; Rodríguez, A; Rosal, R | 1 |
| Elisaf, MS; Kei, A; Milionis, HJ; Moutzouri, E | 1 |
| Barreiro, JC; Cass, QB; Madureira, TV; Rocha, E; Rocha, MJ; Tiritan, ME | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Blasetto, JW; Carlson, DM; Fukumoto, SM; Khurmi, NS; Rosenson, RS; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Carlson, DM; Gold, A; Jacobson, TA; Kelly, MT; Pepine, CJ; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Campbell, J; Mohiuddin, SM | 1 |
| Carlson, DM; Hirshberg, B; Kelly, MT; Rosenson, RS; Setze, CM; Stolzenbach, JC; Williams, LA | 1 |
| Bittner, V; Goldberg, AC; Kelly, MT; Lele, A; Pepine, CJ; Setze, CM; Sleep, DJ; Thakker, K | 1 |
| Corraliza, L; Garcia-Ramírez, M; Hernández, C; Simó, R; Villarroel, M | 1 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Davis, MW; Digiacinto, J; Godfrey, AR | 1 |
| Guo, W; Hernández, C; Roy, S; Simó, R; Trudeau, K; Villarroel, M | 1 |
| Bandgar, BP; Khan, F; Mookkan, J; Sarangdhar, RJ; Shetty, P; Singh, G | 1 |
| Agüera, A; del Mar Gómez-Ramos, M; Fernández Alba, AR; García-Calvo, E; Rosal, R; Santiago, J | 1 |
| Guo, J; Meng, F; Song, X; Wang, G; Zhao, Y; Zhong, B | 1 |
| He, XH; Jia, HY; Li, W; Shi, WG; Zhong, BH | 1 |
| Bielecka, A; Bułdak, Ł; Duława-Bułdak, A; Krysiak, R; Madej, A; Okopień, B; Łabuzek, K | 1 |
| Ballantyne, CM; Belmont, J; Brautbar, A; Jones, PH; Nambi, V; Virani, SS | 1 |
| Davidson, MH; Ferdinand, KC; Kelly, MT; Setze, CM | 1 |
| Kaushik, M; Mohiuddin, SM; Saurav, A | 1 |
| Davis, TM; Wong, RP | 1 |
| Cruzeiro, C; Madureira, TV; Monteiro, RA; Rocha, E; Rocha, MJ; Rodrigues, I | 1 |
| Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB | 1 |
| Filippatos, TD | 1 |
| Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Li, MD; Liu, M; Ma, J; Phillips, DL; Su, T | 1 |
| Chen, H; Geng, Q; Lee, C; Liang, W; Ren, J | 1 |
| Ballantyne, CM; Barbalic, M; Belmont, J; Brautbar, A; Chen, F; Hegele, RA; Scherer, S; Virani, SS | 1 |
| Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kono, M; Matsushita, T; Miyamoto, L; Nemoto, H; Taoka, C; Tomida, Y; Tsuchiya, K; Watanabe, M | 1 |
| Burns, KM; Carlson, DM; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Weinstein, DL; Williams, LA | 1 |
| Borkar, N; Gan, Y; Holm, R; Mu, H; Müllertz, A; Xia, D; Yang, M | 1 |
| Farkas-Epperson, M; Le, NA; Sweeney, ME; Virgil Brown, W; Wilson, PW | 1 |
| Fukuhara, H; Hoshina, M; Karahashi, M; Kawashima, Y; Kudo, N; Mitsumoto, A; Sakamoto, T; Yamazaki, T | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
| Joshi, PH; Lele, A; Rinehart, S; Sharma, A; Thakker, KM; Voros, S | 1 |
| Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA | 1 |
| Chen, Q; Cheng, R; Ding, L; Ma, JX; Moore, R; Moran, E; Takahashi, Y; Wang, Z | 1 |
| Chachad, SS; Gole, M; Malhotra, G; Naidu, R | 1 |
| Cheng, R; Ding, L; Ma, JX; Moran, E; Wang, Z; Xu, X | 1 |
| Girisham, S; Govardhan, P; Prasad, GS; Reddy, SM | 1 |
| Bogdanov, P; Carvalho, AR; Corraliza, L; Hernández, C; Simó, R | 1 |
| Ansquer, JC; Aubonnet, P; MacuFEN Study Investigators, FT; Massin, P; Peto, T | 1 |
| Nie, J; Wang, F; Wang, H; Zhang, C | 1 |
| Chen, G; Chen, L; Cheng, J; Gui, L; Li, C; Lu, Y; Shen, B; Zhang, Q | 1 |
| Cahay, B; Coffiner, M; De Niet, S; Lebrun, S; Rennie, TW; Streel, B; Tremege, M; Verbeeck, RK | 1 |
| Ayyala, R; Blake, DA; Culicchia, F; Grabacka, M; John, VT; Ponnusamy, T; Reiss, K; Rutkowska, M; Vashistha, H; Waligorski, P; Wilk, A; Wisniewska-Becker, A; Wyczechowska, D; Zapata, A | 1 |
| Dahlgren, D; Lennernäs, H; Roos, C; Sjögren, E | 1 |
| Garcia-Ramírez, M; Hernández, C; Palomer, X; Simó, R; Vázquez-Carrera, M | 1 |
| Choi, HG; Jin, SG; Kim, DW; Kim, JO; Kim, KS; Kim, YH; Mustapha, O; Woo, JS; Yong, CS; Yousaf, AM | 1 |
| Anai, M; Gonzalez, FJ; Ikeda, K; Inagaki, T; Kodama, T; Matsumura, Y; Raza-Iqbal, S; Sakai, J; Taguchi, A; Tanaka, T | 1 |
| Han, HK; Shao, Y; Yang, L | 2 |
| Hernández, C; Kim, D; Roy, S; Simó, R | 1 |
| Ansquer, JC; Driessen, S; Nauta, J; Ouwens, MJ | 1 |
| Andreu, I; Jiménez, MC; Miranda, MA; Monje, VT; Vayá, I | 1 |
| Alfaro, RM; Calderón, MM; Gordon, LA; Hadigan, C; Kovacs, JA; Malati, CY; McLaughlin, M; Penzak, SR | 1 |
| Bose, N; Kishan, AU; Modjtahedi, BS; Morse, L; Papakostas, TD; Vavvas, DG | 1 |
| Cho, KH; Choi, HG; Jin, SG; Kim, DS; Kim, DW; Kim, JH; Kim, JO; Kim, KS; Li, DX; Woo, JS; Yong, CS | 1 |
| Du, Y; Li, P; Liu, H; Liu, M; Liu, X; Wang, J; Wang, M; Wei, X; Zhang, J | 1 |
| Kanavi, M; Malátková, P; Nobilis, M; Wsól, V | 1 |
| Dullens, SP; Konings, M; Mensink, RP; Plat, J; Popeijus, HE; van der Krieken, SE | 1 |
| Liu, IM; Liu, WY; Tzeng, TF | 1 |
| Amenitsch, H; Müllertz, A; Rades, T; Siqueira, SDVS; Tran, T | 1 |
| Kim, TK | 1 |
| Chen, Q; Du, Y; Ma, JX; Matlock, G; Qiu, F; Wang, X; Zhou, K | 1 |
| Deepika, G; Govardhan, P; Prasad, GS; Sashidhar, RB; Vakdevi, V | 1 |
| Coors, A; Gildemeister, D; Hassold, E; Kühnen, U; Polleichtner, C; Sacher, F; Vollmar, P | 1 |
| Chen, J; Li, C; Lu, Y; Peijnenburg, WJGM; Qu, J; Xie, Q; Zhang, YN; Zhao, J; Zhou, Y | 1 |
| Han, JS; Hwang, GS; Jung, Y; Kim, K; Lee, HY; Lee, JH; Lee, SH; Namgung, J; Suh, J | 1 |
| Bursill, CA; Jenkins, AJ; Keech, AC; King, EJ; Lam, YT; Lecce, L; Ng, MKC; Rajamani, K; Simpson, PJL; Solly, EL; Tan, JTM; Yuan, J | 1 |
| Chen, Q; Deng, G; Du, Y; Ma, JX; Ma, X; Matlock, G; Meng, T; Qiu, F; Shao, Y; Wang, X; Wu, W; Xu, Q; Zhou, K | 1 |
| Bagger, C; Janfelt, C; Müllertz, A; Plum, J; Strindberg, S | 1 |
| Mudhakir, D; Pamudji, JS; Suhery, WN; Sumirtapura, YC | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Chan, KC; Huang, J; Zhou, R | 1 |
| Feng, Y; Li, S; Li, W; Liu, X; Tzekov, R; Wang, X; Wu, Y; Xu, Y; Yang, J; Yu, C | 1 |
19 review(s) available for fenofibrate and fenofibric acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol | 1983 |
Micronized fenofibrate: a new fibric acid hypolipidemic agent.
Topics: Clinical Trials as Topic; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 1999 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver Diseases; Obesity; Pancreatitis; Pregnancy; Pregnancy Complications | 2001 |
Treatment of hyperlipidaemia with fenofibrate and related fibrates.
Topics: Angiography; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Myopathy with statin-fibrate combination therapy: clinical considerations.
Topics: Clofibric Acid; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents | 2009 |
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Blood Glucose; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fenofibrate; Fluorouracil; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Treatment Outcome | 2009 |
Medicinal chemistry of drugs used in diabetic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus; Endothelin-1; Fenofibrate; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Receptors, Angiotensin | 2010 |
Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Delayed-Action Preparations; Drug Delivery Systems; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2010 |
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic | 2010 |
The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Topics: Choline; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2010 |
Fenofibric acid for hyperlipidemia.
Topics: Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents | 2012 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Creatine Kinase; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Randomized Controlled Trials as Topic; Triglycerides | 2013 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-Like Growth Factor Binding Protein 3; Macular Edema; Protective Factors; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Endothelial Growth Factor A | 2014 |
Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy.
Topics: Apolipoproteins B; Cholesterol; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Triglycerides | 2015 |
Lipids and Diabetic Retinopathy.
Topics: Diabetic Retinopathy; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids | 2016 |
46 trial(s) available for fenofibrate and fenofibric acid
| Article | Year |
|---|---|
Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.
Topics: Adult; Anticholesteremic Agents; Capsules; Clinical Trials as Topic; Drug Administration Schedule; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates | 1988 |
Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Propionates; Triglycerides | 1987 |
Effects of several lipid-lowering drugs on skin total and esterified cholesterol.
Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Probucol; Random Allocation; Skin | 1986 |
Cochleovestibular disorders and hyperlipidemia. A controlled trial with fenofibrate.
Topics: Adult; Aged; Clinical Trials as Topic; Cochlea; Double-Blind Method; Female; Fenofibrate; Hearing; Hearing Disorders; Humans; Hyperlipidemias; Hypolipidemic Agents; Labyrinth Diseases; Male; Middle Aged; Propionates; Random Allocation; Vestibule, Labyrinth | 1986 |
Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Propionates; Sex Factors; Triglycerides | 1985 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Propionates; Time Factors | 1985 |
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
[Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clinical Trials as Topic; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Propionates; Triglycerides | 1984 |
Effect of short-term treatment with bezafibrate and fenofibrate on biliary lipid metabolism in patients with hyperlipoproteinaemia.
Topics: Bezafibrate; Bile; Cholesterol; Female; Fenofibrate; Gallbladder; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Male; Propionates; Triglycerides | 1984 |
A comparison of fenofibrate and clofibrate hypolipidemic effects.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Fenofibrate; Humans; Hyperlipidemias; Middle Aged; Propionates; Triglycerides | 1980 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1982 |
Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.
Topics: Adult; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Middle Aged; Propionates; Transaminases; Uric Acid; Uricosuric Agents | 1980 |
Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Drug Administration Schedule; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies | 1997 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Biological Availability; Cross-Over Studies; Drug Antagonism; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Pravastatin | 2000 |
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2003 |
Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.
Topics: Adult; Azetidines; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Glucuronides; Humans; Hypolipidemic Agents; Male; Middle Aged | 2006 |
Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
Topics: C-Reactive Protein; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged | 2006 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
Topics: Adult; Cross-Over Studies; Drug Interactions; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Topics: Adult; Aged; Anticholesteremic Agents; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Puerto Rico; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Young Adult | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Biological Availability; Drug Delivery Systems; Fenofibrate; Half-Life; Humans; Hypolipidemic Agents; Injections, Intravenous; Intestinal Absorption; Male; Metabolic Clearance Rate; Middle Aged; Young Adult | 2010 |
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Humans; Hypercholesterolemia; Hypertriglyceridemia; Liver; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Topics: Adult; Aged; Analysis of Variance; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Treatment Outcome | 2011 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Cross-Over Studies; Dietary Fats; Fasting; Female; Fenofibrate; Food-Drug Interactions; Humans; Male; Prodrugs; Tablets; Therapeutic Equivalency; Young Adult | 2011 |
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Topics: Apolipoprotein C-III; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Polymorphism, Single Nucleotide; Regression Analysis; Triglycerides | 2012 |
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Young Adult | 2013 |
Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Copper; Cross-Over Studies; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Oxygen; Postprandial Period; Triglycerides | 2013 |
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2014 |
Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Fenofibrate; Healthy Volunteers; Humans; Male; Middle Aged; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2014 |
Effects of fenofibric acid on diabetic macular edema: the MacuFen study.
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Female; Fenofibrate; Humans; Macula Lutea; Macular Edema; Male; Middle Aged; Prospective Studies; Tomography, Optical Coherence; Triglycerides; Visual Acuity | 2014 |
The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Capsules; Chromatography, Liquid; Cross-Over Studies; Dietary Fats; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Nanoparticles; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2015 |
Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
Topics: Adult; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lopinavir; Male; Middle Aged; Ritonavir; Young Adult | 2016 |
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Lipid Metabolism; Male; Middle Aged | 2018 |
152 other study(ies) available for fenofibrate and fenofibric acid
| Article | Year |
|---|---|
Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.
Topics: Administration, Oral; Animals; Apolipoprotein A-I; Binding, Competitive; Biological Availability; Cell Line; Dogs; Drug Design; Humans; Mice; Mice, Transgenic; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Transcription Factors; Transfection; Triazoles | 2003 |
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship; Triglycerides | 2008 |
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity | 2008 |
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics | 2009 |
The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates.
Topics: Amino Acid Substitution; Animals; Binding Sites; Cells, Cultured; Fatty Acid Transport Proteins; Fatty Acid-Binding Proteins; Fenofibrate; Fibric Acids; Gene Expression Regulation; Hot Temperature; Humans; Hypolipidemic Agents; Ligands; Liver; Mice; Phytanic Acid; Polymorphism, Single Nucleotide; PPAR alpha; Protein Stability; Protein Structure, Secondary; Rats; Recombinant Proteins | 2013 |
Peroxisome proliferating sulphur- and oxy-substituted fatty acid analogues are activated to acyl coenzyme A thioesters.
Topics: Animals; Clofibric Acid; Enzyme Activation; Fatty Acids; Fenofibrate; Liver; Male; Microbodies; Oxides; Palmitoyl Coenzyme A; Palmitoyl-CoA Hydrolase; Rats; Rats, Inbred Strains; Sulfides; Sulfoxides | 1991 |
Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?
Topics: Adult; Chromatography, High Pressure Liquid; Clofibric Acid; Female; Fenofibrate; Glucuronates; Humans; Hypolipidemic Agents; Male; Middle Aged; Molecular Structure; Polymorphism, Genetic; Reference Values | 1991 |
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents.
Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Epoxide Hydrolases; Fenofibrate; gamma-Glutamyltransferase; Glucuronosyltransferase; Hypolipidemic Agents; Lipids; Liver; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1987 |
[Acquired ichthyosis during lipid-normalizing treatment].
Topics: Anticholesteremic Agents; Fenofibrate; Humans; Ichthyosis; Male; Middle Aged; Propionates | 1986 |
Effect of fenofibrate on apolipoprotein B containing lipoprotein particles.
Topics: Apolipoproteins B; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Immunoenzyme Techniques; Lipoproteins; Male; Propionates; Random Allocation | 1988 |
Changes in plasma activities of lipolytic enzymes and lipids of normolipidemic subjects given phenobarbital, a strong microsomal inducer, alone or in combination with fenofibrate.
Topics: Adult; Antipyrine; Enzyme Induction; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipids; Lipoprotein Lipase; Liver; Male; Microsomes, Liver; Phenobarbital; Phosphatidylcholine-Sterol O-Acyltransferase; Propionates | 1988 |
Simple and rapid method for determining procetofenic acid, an active metabolite of procetofen, in biological fluids by solid-phase extraction and high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Female; Fenofibrate; Humans; Indicators and Reagents; Kinetics; Male; Propionates | 1986 |
Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
Topics: Adult; Apolipoproteins; Body Weight; Cholesterol; Cholesterol, HDL; Colestipol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Polyamines; Propionates | 1986 |
[Hepatitis caused by fenofibrate].
Topics: Aged; Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Hypolipidemic Agents; Propionates | 1986 |
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Middle Aged; Phospholipids; Propionates; Triglycerides | 1986 |
Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Kinetics; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Propionates | 1985 |
Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholelithiasis; Cholesterol; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Propionates | 1985 |
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Fenofibrate; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Kinetics; Male; Middle Aged; Monocytes; Propionates | 1985 |
Biological variations in hyperlipidemic children and adolescents treated with fenofibrate.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bilirubin; Child; Child, Preschool; Cholesterol; Fenofibrate; gamma-Glutamyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Propionates; Transaminases; Triglycerides; Uric Acid | 1981 |
[Action of fenofibrate in hypercholesterolemic children. 18-month follow-up].
Topics: Child; Cholesterol; Female; Fenofibrate; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Propionates; Statistics as Topic; Time Factors | 1984 |
[The effect of fenofibrate on the lipid level in diabetic patients].
Topics: Aged; Diabetes Complications; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates | 1983 |
Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Propionates; Triglycerides | 1984 |
Effect of fenofibrate and LF 2151 on hepatic peroxisomes in hamsters.
Topics: Acyl Coenzyme A; Animals; Anticholesteremic Agents; Carnitine O-Acetyltransferase; Catalase; Cholesterol; Cricetinae; Fenofibrate; Liver; Male; Mesocricetus; Microbodies; Microscopy, Electron; Mitochondria, Liver; Propionates | 1984 |
Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Lipoproteins, VLDL; Male; Middle Aged; Propionates; Triglycerides | 1984 |
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.
Topics: Adult; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipolysis; Lipoprotein Lipase; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Probucol; Triglycerides | 1983 |
Plasma lecithin:cholesterol acyltransferase -- reference values and effects of xenobiotics.
Topics: Adolescent; Adult; Aging; Alcohol Drinking; Anticonvulsants; Child; Child, Preschool; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Quality Control; Reference Values; Sex Factors | 1983 |
Effects of benfluorex and fenofibrate treatment on mitochondrial and peroxisomal marker enzymes in rat liver.
Topics: Animals; Catalase; Fenfluramine; Fenofibrate; Glutamate Dehydrogenase; Hypolipidemic Agents; Liver; Male; Microbodies; Mitochondria, Liver; Propionates; Rats; Rats, Inbred Strains | 1984 |
[Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].
Topics: Adult; Aged; Animals; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Liver; Male; Microbodies; Microscopy, Electron; Middle Aged; Propionates | 1984 |
Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Microbodies; Microscopy, Electron; Middle Aged; Propionates | 1983 |
Application of the concanavalin A precipitation technique in an evaluation of fenofibrate action on cholesterolemia in IIa and IIb hyperlipemic subjects.
Topics: Adult; Aged; Aging; Anticholesteremic Agents; Chemical Precipitation; Cholesterol; Concanavalin A; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Propionates; Sex Factors | 1983 |
Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Diet; Female; Fenofibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Propionates; Triglycerides | 1983 |
Fenofibrate and human liver. Lack of proliferation of peroxisomes.
Topics: Adult; Aged; Cell Division; Diet; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Liver; Male; Microbodies; Microscopy, Electron; Middle Aged; Organoids; Propionates | 1983 |
Evidence for the inhibition of platelet-derived growth factor induced rat smooth muscle cells DNA synthesis by fenofibric acid at the Go/G1 cell cycle level.
Topics: Animals; Aorta; Cell Division; Cells, Cultured; Cholesterol; Cholesterol, LDL; DNA; Fenofibrate; Growth Inhibitors; Growth Substances; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interphase; Lipoproteins, LDL; Male; Muscle, Smooth, Vascular; Peptides; Platelet-Derived Growth Factor; Propionates; Rats; Rats, Inbred Strains | 1983 |
Effects of a salt of cholestyramine and 2-[4-(p-chlorobenzoyl)phenoxy]2-methyl propionic acid (alpha-1081) on biliary lipid secretion in rats.
Topics: Animals; Bile; Bile Acids and Salts; Cholestenes; Cholesterol; Drug Combinations; Fenofibrate; Hypolipidemic Agents; Lipid Metabolism; Male; Phospholipids; Propionates; Rats; Rats, Inbred Strains | 1981 |
Plasma lipid concentrations and lecithin: cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.
Topics: Colestipol; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Polyamines; Propionates | 1981 |
Rapid determination of procetofenic acid in plasma by high-performance liquid chromatography.
Topics: Animals; Chromatography, High Pressure Liquid; Fenofibrate; Male; Propionates; Rats; Rats, Inbred Strains | 1982 |
[Muscular toxicity due to fenofibrate. Apropos of a case].
Topics: Aged; Female; Fenofibrate; Humans; Hypolipidemic Agents; Muscular Diseases; Propionates | 1982 |
Inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured human blood mononuclear cells by procetofenic acid.
Topics: Adult; Cells, Cultured; Ethanol; Fenofibrate; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lipoproteins; Male; Mevalonic Acid; Middle Aged; Monocytes; Propionates | 1982 |
Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.
Topics: Adult; Aged; Female; Fenofibrate; Humans; Kidney Failure, Chronic; Kinetics; Male; Middle Aged; Propionates; Renal Dialysis | 1982 |
[Hypolipemic action of various drugs in rats poisoned with Triton WR 1339].
Topics: Animals; Cholesterol; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Male; Nicotinic Acids; Polyethylene Glycols; Pyridinolcarbamate; Rats | 1982 |
Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
Topics: Adult; Aspartate Aminotransferases; Cholesterol; Cholestyramine Resin; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Middle Aged; Propionates; Triglycerides | 1982 |
[Metabolism of fenofibrate and fenofibric acid in vivo and in cultures of liver epithelial cells (author's transl)].
Topics: Animals; Cells, Cultured; Chromatography, Gas; Epithelial Cells; Epithelium; Fenofibrate; Humans; Hypolipidemic Agents; Liver; Male; Mass Spectrometry; Propionates; Rats | 1980 |
Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate.
Topics: Animals; Carcinogens; Clofibrate; DNA; Female; Fenofibrate; Liver; Male; Propionates; Protein Binding; Rats | 1981 |
Inhibition of membrane-bound hepatic 3 hydroxy-3 methyl glutaryl CoA reductase as the consequence of altered membrane fluidity.
Topics: Animals; Chromatography, Affinity; Fenofibrate; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Membrane Fluidity; Microsomes, Liver; Rats | 1981 |
Effect of feeding clofibrate-containing diet on the hepatic NAD+ level in rats.
Topics: Animals; Clofibrate; Diet; Diethylhexyl Phthalate; Fenofibrate; Hypolipidemic Agents; Liver; Male; Microbodies; NAD; Rats; Rats, Sprague-Dawley | 1995 |
Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes.
Topics: Animals; Cells, Cultured; Clofibric Acid; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Fenofibrate; Fibric Acids; Guinea Pigs; Humans; Liver; Male; Mass Spectrometry; Microbodies; Mixed Function Oxygenases; Palmitoyl Coenzyme A; Rats; Rats, Wistar; Species Specificity; Time Factors; Tumor Cells, Cultured | 1995 |
Lack of a genetic polymorphism in the glucuronidation of fenofibric acid.
Topics: Adolescent; Adult; Female; Fenofibrate; Glucuronates; Humans; Male; Middle Aged; Models, Biological; Polymorphism, Genetic; White People | 1995 |
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis.
Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein | 1994 |
Fenofibric acid modulates the human apolipoprotein A-IV gene expression in HepG2 cells.
Topics: Apolipoproteins; Apolipoproteins A; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Tumor Cells, Cultured | 1994 |
Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Evidence for protein binding via a Schiff's base mechanism.
Topics: Buffers; Clofibric Acid; Fenofibrate; Glucuronates; Humans; In Vitro Techniques; Protein Binding; Serum Albumin; Solutions | 1993 |
Effect of chloride channel blockers on the cardiac CFTR chloride and L-type calcium currents.
Topics: Animals; Anthracenes; Calcium; Calcium Channel Blockers; Chloride Channels; Chlorides; Clofibric Acid; Colforsin; Cystic Fibrosis Transmembrane Conductance Regulator; Fenofibrate; Gemfibrozil; Glycolates; Guinea Pigs; Ion Transport; Mice; Myocardium; ortho-Aminobenzoates; Patch-Clamp Techniques; Stilbenes | 1996 |
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Cell Line; Dimerization; DNA; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Myocardium; Organ Specificity; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 1996 |
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
Topics: Bezafibrate; Calibration; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hypolipidemic Agents; Reproducibility of Results; Sensitivity and Specificity | 1996 |
[Thyroid myopathy disclosed by a fibrate].
Topics: Aged; Fenofibrate; Humans; Hypolipidemic Agents; Hypothyroidism; Male; Rhabdomyolysis | 1997 |
Release of inflammatory mediators (PGE2, IL-6) by fenofibric acid-photosensitized human keratinocytes and fibroblasts.
Topics: Cells, Cultured; Dinoprostone; Fenofibrate; Fibroblasts; Humans; Hypolipidemic Agents; Interleukin-1; Interleukin-6; Keratinocytes; Male; Photosensitizing Agents; Skin; Ultraviolet Rays | 1998 |
The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates.
Topics: Animals; Apolipoprotein A-I; DNA-Binding Proteins; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Lipid Metabolism; Lipoproteins; Liver; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Repressor Proteins; Retinoid X Receptors; RNA, Messenger; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 1998 |
[High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine].
Topics: Administration, Oral; Adult; Aged; Anticholesteremic Agents; Chromatography, High Pressure Liquid; Fenofibrate; Humans; Hypolipidemic Agents; Male; Reproducibility of Results | 1998 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
Topics: Aging; Animals; Apolipoprotein C-I; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Fenofibrate; Gene Expression Regulation; Gene Expression Regulation, Developmental; Humans; Hypolipidemic Agents; Kinetics; Liver; Male; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 1999 |
Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.
Topics: Binding Sites; Dimerization; DNA-Binding Proteins; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; Liver; Nuclear Receptor Subfamily 1, Group D, Member 1; Peroxisome Proliferators; Promoter Regions, Genetic; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; RNA, Messenger; Transcription Factors | 1999 |
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates.
Topics: Apolipoprotein A-II; Brefeldin A; Culture Media; DNA, Complementary; Fenofibrate; Humans; Hypolipidemic Agents; Protein Synthesis Inhibitors; RNA, Messenger; Subcellular Fractions; Tissue Distribution; Tumor Cells, Cultured; Viral Core Proteins | 1999 |
Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography.
Topics: Area Under Curve; Chromatography, High Pressure Liquid; Fenofibrate; Humans; Male; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2000 |
A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.
Topics: Animals; Cricetinae; Dietary Fats; Fatty Acids; Fenofibrate; Lipid Metabolism; Male; Mesocricetus; Mitochondria, Liver; Mitochondria, Muscle; Muscle, Skeletal; Oxidation-Reduction; Phenylurea Compounds; Receptors, Cytoplasmic and Nuclear; Time Factors; Transcription Factors; Triglycerides | 2001 |
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
Topics: Butyrates; Cells, Cultured; Down-Regulation; Fenofibrate; Humans; Interleukin-1; Lipopolysaccharides; Macrophages; Monocytes; Peroxisome Proliferators; Phenylurea Compounds; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thromboplastin; Transcription Factors | 2001 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Triglycerides | 2001 |
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; Cell Line; Culture Media, Serum-Free; Cyclic N-Oxides; DNA-Binding Proteins; Enzyme Inhibitors; Fenofibrate; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Mercaptoethanol; Phosphorylation; Promoter Regions, Genetic; Pyridines; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; rho GTP-Binding Proteins; Signal Transduction; Transcription Factors | 2001 |
Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer.
Topics: Anticholesteremic Agents; Benzophenones; Cytochrome c Group; DNA; DNA Damage; Electron Spin Resonance Spectroscopy; Fenofibrate; Ketoprofen; Oligodeoxyribonucleotides; Photosensitizing Agents; Polarography | 2001 |
A laser flash photolysis study of fenofibric acid in aqueous buffered media: unexpected triplet state inversion in a derivative of 4-alkoxybenzophenone.
Topics: Benzophenones; Buffers; Fenofibrate; Lasers; Photolysis; Water | 2002 |
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.
Topics: 5' Flanking Region; Anticholesteremic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Dactinomycin; DNA; Endothelium, Vascular; Enzyme Inhibitors; Fenofibrate; Fibroblast Growth Factor 2; Flavonoids; Humans; Plasminogen Activator Inhibitor 1; Protein Synthesis Inhibitors; RNA, Messenger; Transcription, Genetic; Umbilical Veins | 2002 |
Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells.
Topics: Cells, Cultured; Chemokine CCL2; Cholesterol, LDL; Dilazep; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Fenofibrate; Gene Expression Regulation; Glycolates; Humans; RNA, Messenger | 2003 |
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Dihydroergocryptine; Fenofibrate; Humans; Hypolipidemic Agents; Simvastatin; Swine; Transfection | 2004 |
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2004 |
Fenofibrate and fenofibric acid analysis by capillary electrophoresis.
Topics: Electrophoresis, Capillary; Fenofibrate; Humans; Sodium Dodecyl Sulfate | 2004 |
Fenofibrate, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 close KATP channels and induce insulin secretion.
Topics: Animals; Chromans; Cricetinae; Fenofibrate; Immunologic Factors; Insulin; Insulin Secretion; Membrane Proteins; Potassium Channels; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2004 |
Photosensitization of thymine nucleobase by benzophenone derivatives as models for photoinduced DNA damage: Paterno-Büchi vs energy and electron transfer processes.
Topics: Benzophenones; DNA Damage; Energy Transfer; Fenofibrate; Ketoprofen; Models, Biological; Photosensitizing Agents; Thymine Nucleotides; Ultraviolet Rays | 2004 |
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.
Topics: Biopsy; Carcinoma, Hepatocellular; Cell Line; DNA Primers; Fenofibrate; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Immunohistochemistry; Liver; Liver Neoplasms; PPAR alpha; Transcription, Genetic; Transfection | 2005 |
Fenofibric acid.
Topics: Anticholesteremic Agents; Crystallography, X-Ray; Fenofibrate; Hydrogen Bonding; Models, Molecular; Molecular Conformation | 2005 |
Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.
Topics: Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line; DNA-Binding Proteins; Fenofibrate; Gene Expression; Hypolipidemic Agents; Lipoproteins, HDL; Liver X Receptors; Mice; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Transcription, Genetic | 2005 |
Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.
Topics: Acetates; Calibration; Carbamazepine; Chromatography; Chromatography, Ion Exchange; Chromatography, Liquid; Fenofibrate; Fluorobenzenes; Freezing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ions; Male; Mass Spectrometry; Models, Chemical; Pyrimidines; Quality Control; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Temperature; Time Factors | 2005 |
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
Topics: Adiponectin; Alitretinoin; Animals; Caco-2 Cells; Cell Line; CHO Cells; Chromans; Cricetinae; DNA-Binding Proteins; Fenofibrate; HeLa Cells; Hepatocytes; Humans; Hydroxycholesterols; Liver X Receptors; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Pioglitazone; PPAR alpha; Receptors, Adiponectin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Retinoid X Receptors; Thiazolidinediones; Tretinoin; Troglitazone; Up-Regulation | 2005 |
The transfer of a LC-UV method for the determination of fenofibrate and fenofibric acid in Lidoses: use of total error as decision criterion.
Topics: Chromatography, Liquid; Fenofibrate; Research Design; Spectrophotometry, Ultraviolet | 2006 |
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
Topics: Analgesics; Animals; DNA, Complementary; Drug Tolerance; Fenofibrate; Formaldehyde; Hyperalgesia; Hypolipidemic Agents; Immunoblotting; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nociceptors; Pain Measurement; Potassium Channels, Calcium-Activated; PPAR alpha; Rats; Rats, Sprague-Dawley; RNA; Sciatica | 2006 |
Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.
Topics: Adiponectin; Aldehyde Oxidoreductases; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Fatty Liver; Fenofibrate; Hepatocytes; Humans; Rats; Rats, Wistar | 2006 |
Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum.
Topics: Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Drug Stability; Fenofibrate; Humans; Hypolipidemic Agents; Sensitivity and Specificity; Solid Phase Extraction | 2007 |
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Catalysis; Drug Interactions; Fenofibrate; Gemfibrozil; Glucuronic Acid; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lactones; Microsomes, Liver; Models, Biological; Molecular Structure; Pyrroles; Recombinant Proteins; Tandem Mass Spectrometry; Uridine Diphosphate Glucuronic Acid | 2007 |
A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
Topics: Adiponectin; Adipose Tissue; Animals; Butyrates; Dietary Fats; DNA, Complementary; Dogs; Dose-Response Relationship, Drug; Fatty Acids; Fenofibrate; Genes, Reporter; Humans; Hypolipidemic Agents; Insulin Resistance; Lipids; Liver; Luciferases; Male; Obesity; Oxidation-Reduction; PPAR alpha; PPAR delta; PPAR gamma; Rats; Reverse Transcriptase Polymerase Chain Reaction; Transcriptional Activation | 2008 |
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrocarbons, Fluorinated; Hyperlipoproteinemia Type II; Lipid Metabolism; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; Pravastatin; Promoter Regions, Genetic; Proprotein Convertase 5; Proprotein Convertase 9; Proprotein Convertases; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Serine Endopeptidases; Sulfonamides; Up-Regulation | 2008 |
An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.
Topics: Chromatography, Liquid; Fenofibrate; Humans; Molecular Structure; Pravastatin; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2008 |
PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
Topics: Adult; Alanine Transaminase; Biomarkers; Chemical and Drug Induced Liver Injury; Chromatin; Electrophoretic Mobility Shift Assay; Fenofibrate; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hypolipidemic Agents; Immunoprecipitation; Luciferases; Male; Mutagenesis; Plasmids; PPAR alpha; Promoter Regions, Genetic; Response Elements; RNA; Transfection | 2008 |
Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein.
Topics: Animals; Binding Sites; Caco-2 Cells; Enterocytes; Fatty Acid-Binding Proteins; Fatty Acids; Fenofibrate; Humans; Immunohistochemistry; Ligands; Microscopy, Confocal; Pharmaceutical Preparations; Rats; Temperature | 2009 |
Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.
Topics: Calibration; Chromatography, High Pressure Liquid; Drug Stability; Fenofibrate; Humans; Least-Squares Analysis; Linear Models; Male; Mefenamic Acid; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Therapeutic Equivalency | 2009 |
Fenofibric Acid (trilipix).
Topics: Coronary Disease; Drug Approval; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; United States | 2009 |
Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.
Topics: Animals; Animals, Newborn; Blood-Brain Barrier; Brain; Capillary Permeability; Cell Proliferation; Cells, Cultured; Claudin-5; Coculture Techniques; Dose-Response Relationship, Drug; Endothelial Cells; Fenofibrate; Gene Expression Regulation; Glucose; Hypolipidemic Agents; Hypoxia; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuroglia; PPAR alpha; Time Factors; von Willebrand Factor | 2009 |
In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.
Topics: Cell Line; Fenofibrate; Glucuronides; Glucuronosyltransferase; Humans; Isoenzymes; Microsomes, Liver; Recombinant Proteins | 2009 |
Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.
Topics: Butyrates; Fatty Acids, Unsaturated; Fenofibrate; Humans; Ligands; Maltose-Binding Proteins; Mediator Complex Subunit 1; Models, Molecular; Periplasmic Binding Proteins; Phenylurea Compounds; PPAR alpha; Propionates; Protein Binding; Protein Structure, Tertiary; Recombinant Fusion Proteins; Thiazoles | 2010 |
Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PPAR alpha | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes.
Topics: Acyltransferases; Animals; ATP-Binding Cassette Transporters; Caveolin 1; Fenofibrate; Hepatocytes; Male; Membrane Microdomains; Membrane Proteins; Mice; Mice, Knockout; Peroxins; Peroxisomes; Rats; Rats, Wistar; Subcellular Fractions | 2010 |
Catalytic ozonation of fenofibric acid over alumina-supported manganese oxide.
Topics: Aluminum Oxide; Anticholesteremic Agents; Catalysis; Fenofibrate; Hydroxyl Radical; Kinetics; Manganese Compounds; Oxides; Ozone | 2010 |
Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal).
Topics: Carbamazepine; Chromatography, Liquid; Diazepam; Environmental Monitoring; Fenofibrate; Pharmaceutical Preparations; Portugal; Propranolol; Risk Assessment; Rivers; Solid Phase Extraction; Sulfamethoxazole; Trimethoprim; Water Pollutants, Chemical | 2010 |
Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.
Topics: Aged; AMP-Activated Protein Kinases; Biological Transport; Blood-Retinal Barrier; Cell Line; Cell Membrane Permeability; Dextrans; Diabetic Retinopathy; Dose-Response Relationship, Drug; Fenofibrate; Fluorescein-5-isothiocyanate; Glucose; Humans; Hypolipidemic Agents; Interleukin-1beta; Macular Edema; Retinal Pigment Epithelium; Tight Junctions | 2011 |
Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.
Topics: Anticholesteremic Agents; Blotting, Western; Capillary Permeability; Cells, Cultured; Claudin-1; Collagen Type IV; Dextrans; Diabetes Complications; Dose-Response Relationship, Drug; Fenofibrate; Fibronectins; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique, Indirect; Glucose; Humans; Interleukin-1beta; Membrane Proteins; Microscopy, Confocal; Phosphoproteins; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium-Potassium-Exchanging ATPase; Up-Regulation; Zonula Occludens-1 Protein | 2011 |
Synthesis and biological evaluation of orally active hypolipidemic agents.
Topics: Administration, Oral; Animals; Cholesterol; Esters; Fenofibrate; Hypolipidemic Agents; Male; Mice; Models, Chemical; Molecular Structure; Particle Size; Prodrugs; Triglycerides; X-Ray Diffraction | 2011 |
Oxidation by-products and ecotoxicity assessment during the photodegradation of fenofibric acid in aqueous solution with UV and UV/H2O2.
Topics: Fenofibrate; Hydrogen Peroxide; Kinetics; Oxidation-Reduction; Photochemistry; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Ultraviolet Rays | 2011 |
Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma.
Topics: Animals; Anticholesteremic Agents; Chromatography, Liquid; Fenofibrate; Linear Models; Liquid-Liquid Extraction; Male; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents.
Topics: Animals; Carboxylic Acids; Cholesterol; Diabetes Mellitus, Experimental; Fenofibrate; Flavonoids; Hyperlipidemias; Hypolipidemic Agents; Magnetic Resonance Spectroscopy; Male; Mice; Models, Molecular; Molecular Structure; Polyethylene Glycols; Resveratrol; Stilbenes; Surface-Active Agents; Triglycerides | 2012 |
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
Topics: Adipocytes; Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; In Vitro Techniques; Intra-Abdominal Fat; Male; Middle Aged; Pyrroles; Subcutaneous Fat | 2011 |
In vitro antimalarial activity and drug interactions of fenofibric acid.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Interactions; Fenofibrate; Humans; Plasmodium falciparum | 2012 |
The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal): evaluation of impacts on fish liver, by histopathology, stereology, vitellogenin and CYP1A immunohistochemistry, after sub-acute exposures of the zebrafish model.
Topics: Animals; Carbamazepine; Cytochrome P-450 CYP1A1; Female; Fenofibrate; Fish Proteins; Liver; Male; Portugal; Propranolol; Rivers; Sulfamethoxazole; Trimethoprim; Vitellogenins; Water Pollutants, Chemical; Zebrafish | 2012 |
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Fenofibrate; Ligands; Molecular Sequence Data; Oxazoles; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Transcription, Genetic | 2012 |
Fenofibrates get a second look. Research shows popular drugs fail to lower cardiovascular risk for most patients already taking a statin.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Triglycerides | 2010 |
A time-resolved spectroscopy and density functional theory study of the solvent dependent photochemistry of fenofibric acid.
Topics: Absorption; Acetonitriles; Fenofibrate; Solvents; Spectrum Analysis, Raman; Time Factors; Water | 2013 |
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
Topics: Amino Acids; Apolipoprotein A-I; Apolipoprotein A-V; Apolipoproteins A; Cholesterol, HDL; Dyslipidemias; Female; Fenofibrate; Genetic Variation; Humans; Male; Promoter Regions, Genetic; Triglycerides | 2013 |
A novel prodrug strategy for extremely hydrophobic agents: conjugation to symmetrically branched glycerol trimer improves pharmacological and pharmacokinetic properties of fenofibrate.
Topics: Fenofibrate; Glycerol; Hydrophobic and Hydrophilic Interactions; Prodrugs | 2013 |
Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
Topics: Absorption; Animals; Area Under Curve; Fenofibrate; Lipids; Lipolysis; Male; Particle Size; Rats; Rats, Sprague-Dawley; Solubility; Water | 2014 |
A simple and sensitive method for the determination of fibric acids in the liver by liquid chromatography.
Topics: Acyl-CoA Oxidase; Animals; Bezafibrate; Chromatography, High Pressure Liquid; Clofibric Acid; Fenofibrate; Fibric Acids; Liver; Male; PPAR alpha; Rats; Rats, Wistar; Reproducibility of Results; RNA, Messenger | 2014 |
Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibric acid, or their combination in patients with mixed dyslipidemia.
Topics: Analysis of Variance; Biomarkers; Cholesterol, VLDL; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Linear Models; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Protective and antioxidant effects of PPARα in the ischemic retina.
Topics: Animals; Animals, Newborn; Antioxidants; Apoptosis; Blotting, Western; Cells, Cultured; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fenofibrate; Glial Fibrillary Acidic Protein; Hypolipidemic Agents; Hypoxia-Inducible Factor 1, alpha Subunit; In Situ Nick-End Labeling; Ischemia; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidase 4; NADPH Oxidases; Nerve Tissue Proteins; Oxidative Stress; Oxygen; PPAR alpha; Reactive Oxygen Species; Retinal Diseases; Retinal Vessels | 2014 |
PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway.
Topics: Adenoviridae; Animals; Blotting, Western; Cells, Cultured; Cerebrovascular Circulation; Chemokine CXCL12; Disease Models, Animal; Endothelium, Vascular; Fenofibrate; Flow Cytometry; Fluorescein Angiography; Gene Expression; Hematopoietic Stem Cell Mobilization; Humans; Hypolipidemic Agents; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxygen; PPAR alpha; Real-Time Polymerase Chain Reaction; Retinal Neovascularization; Retinal Vessels; Stem Cells | 2014 |
Fungal mediated generation of mammalian metabolites of fenofibrate and enhanced pharmacological activity of the main metabolite fenofibric acid.
Topics: Animals; Blood Glucose; Chromatography, High Pressure Liquid; Chromatography, Liquid; Fenofibrate; Fungi; Hypolipidemic Agents; Male; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2014 |
Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes.
Topics: Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Fenofibrate; Humans; Male; Mice; Retinal Degeneration | 2015 |
Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.
Topics: Animals; Aorta; Cells, Cultured; Diet, High-Fat; Endoplasmic Reticulum Stress; Endothelial Cells; Endothelium, Vascular; Female; Fenofibrate; Gene Expression Regulation; Lipid Metabolism; Mice; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Palmitic Acid; Rats, Sprague-Dawley; Vasodilation | 2015 |
Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.
Topics: Animals; Biodegradable Plastics; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Fenofibrate; Glioblastoma; Humans; Lactic Acid; Mice; Mice, Nude; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Tissue Distribution | 2015 |
Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data.
Topics: Budesonide; Colon; Cyclosporine; Fenofibrate; Humans; Intestinal Absorption; Intestinal Mucosa; Lisdexamfetamine Dimesylate; Metoprolol; Nifedipine; Pyrimidines; Ranitidine; Rivastigmine; Sumatriptan; Terfenadine; Theophylline | 2015 |
Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity.
Topics: Blood-Retinal Barrier; Capillary Permeability; Cells, Cultured; Cytokines; Diabetic Retinopathy; Down-Regulation; Fenofibrate; Humans; Interleukin-1beta; Interleukin-6; Macular Edema; Retinal Pigment Epithelium; Signal Transduction; Transcription Factor RelA | 2016 |
Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.
Topics: Animals; Area Under Curve; Biological Availability; Carrageenan; Choline; Delayed-Action Preparations; Dogs; Fenofibrate; Solubility; Tablets; Therapeutic Equivalency | 2015 |
Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver.
Topics: Animals; Benzoxazoles; Butyrates; Cell Culture Techniques; Cluster Analysis; Fenofibrate; Gene Expression Profiling; Hepatocytes; Humans; Hypolipidemic Agents; Liver; Mice; Tissue Culture Techniques; Transcriptome | 2015 |
Development of omega-3 phospholipid-based solid dispersion of fenofibrate for the enhancement of oral bioavailability.
Topics: Animals; Drug Liberation; Fatty Acids, Omega-3; Fenofibrate; Hypolipidemic Agents; Intestinal Secretions; Male; Phospholipids; Rats, Sprague-Dawley; Solubility | 2015 |
Beneficial effects of fenofibric acid on overexpression of extracellular matrix components, COX-2, and impairment of endothelial permeability associated with diabetic retinopathy.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Capillary Permeability; Cells, Cultured; Collagen Type IV; Cyclooxygenase 2; Diabetic Retinopathy; Endothelium, Vascular; Fenofibrate; Fibronectins; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique, Indirect; Microscopy, Fluorescence; Rats; Retinal Vessels; Zonula Occludens-1 Protein | 2015 |
Mechanistic Studies on the Photoallergy Mediated by Fenofibric Acid: Photoreactivity with Serum Albumins.
Topics: Animals; Cattle; Dermatitis, Photoallergic; Fenofibrate; Humans; Lasers; Molecular Structure; Photochemical Processes; Serum Albumin | 2016 |
Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Excipients; Fenofibrate; Hypolipidemic Agents; Magnesium; Male; Particle Size; Powders; Rats, Sprague-Dawley; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Technology, Pharmaceutical | 2016 |
Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.
Topics: Animals; Area Under Curve; Biological Availability; Calorimetry, Differential Scanning; Drug Carriers; Drug Liberation; Fenofibrate; Freeze Drying; Lipids; Male; Microscopy, Electron, Scanning; Nanoparticles; Rats, Sprague-Dawley; Solubility; X-Ray Diffraction | 2016 |
Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.
Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Choline; Chromatography, Liquid; Fenofibrate; Half-Life; Limit of Detection; Liquid-Liquid Extraction; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2017 |
In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.
Topics: Alcohol Oxidoreductases; Biocatalysis; Cytosol; Fenofibrate; Humans; Kinetics; Liver; Methanol; Oxidation-Reduction; Stereoisomerism; Subcellular Fractions | 2016 |
C/EBP-β Is Differentially Affected by PPARα Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A-I Production During ER-Stress and Inflammation.
Topics: Apolipoprotein A-I; Atherosclerosis; Butyrates; Caco-2 Cells; CCAAT-Enhancer-Binding Protein-beta; Endoplasmic Reticulum Stress; Fenofibrate; Gene Expression Profiling; Gene Silencing; Hep G2 Cells; Humans; Inflammation; Phenylurea Compounds; PPAR alpha; RNA, Messenger; Thapsigargin | 2017 |
Zerumbone, a Bioactive Sesquiterpene, Ameliorates Diabetes-Induced Retinal Microvascular Damage through Inhibition of Phospho-p38 Mitogen-Activated Protein Kinase and Nuclear Factor-κB Pathways.
Topics: Animals; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Fenofibrate; Glycation End Products, Advanced; Male; Microvessels; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; Retina; Retinal Vessels; Sesquiterpenes; Signal Transduction; Streptozocin; Transcription Factor RelA | 2016 |
In vitro and in vivo performance of monoacyl phospholipid-based self-emulsifying drug delivery systems.
Topics: Animals; Biological Availability; Castor Oil; Chemical Precipitation; Drug Delivery Systems; Emulsions; Fenofibrate; Gastric Mucosa; Glycerides; Intestinal Absorption; Male; Particle Size; Phosphatidylcholines; Rats, Sprague-Dawley | 2017 |
Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Fenofibrate; Hypolipidemic Agents; Limit of Detection; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity | 2017 |
Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration.
Topics: Animals; Blotting, Western; Capillary Permeability; Choroidal Neovascularization; Disease Models, Animal; Fenofibrate; Fluorescein Angiography; Hypolipidemic Agents; Injections, Intraperitoneal; Intercellular Adhesion Molecule-1; Leukostasis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha; Rats; Rats, Inbred BN; Receptors, LDL; Tomography, Optical Coherence; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2017 |
Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Computer Simulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Edema; Fenofibrate; Humans; Hypolipidemic Agents; Inhibitory Concentration 50; Male; Rats; Rats, Wistar | 2018 |
Prospective environmental risk assessment of mixtures in wastewater treatment plant effluents - Theoretical considerations and experimental verification.
Topics: Animals; Araceae; Chlorophyta; Daphnia; Ecotoxicology; Female; Fenofibrate; Fluoxetine; Imidazoles; Male; Pesticides; Pharmaceutical Preparations; Risk Assessment; Toxicity Tests, Chronic; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2018 |
Unveiling the important roles of coexisting contaminants on photochemical transformations of pharmaceuticals: Fibrate drugs as a case study.
Topics: China; Fenofibrate; Gemfibrozil; Hydrogen-Ion Concentration; Light; Models, Theoretical; Molecular Structure; Pharmaceutical Preparations; Photolysis; Rivers; Water Pollutants, Chemical | 2018 |
Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Fenofibrate; Glucose; Hindlimb; Ischemia; Mice; Neovascularization, Pathologic; Signal Transduction | 2019 |
Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Topics: Animals; Capillary Permeability; Choroidal Neovascularization; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Drug Delivery Systems; Drug Liberation; Fenofibrate; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Leukostasis; Mice; Mice, Knockout; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Inbred BN; Retina; Streptozocin; Tissue Distribution; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2019 |
Visualizing the Journey of Fenofibrate through the Rat Gastrointestinal Tract by Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging.
Topics: Administration, Oral; Animals; Fenofibrate; Gastrointestinal Tract; Male; Models, Animal; Molecular Imaging; Prodrugs; Rats; Spatial Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Suspensions; Tissue Distribution | 2021 |
Comparative Bioavailability Study of Solid Self-Nanoemulsifying Drug Delivery System of Fenofibric Acid in Healthy Male Subjects.
Topics: Administration, Oral; Biological Availability; Drug Delivery Systems; Emulsions; Fenofibrate; Humans; Male; Nanoparticles; Particle Size; Solubility; Triglycerides | 2022 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2.
Topics: COVID-19; Fenofibrate; Humans; Molecular Dynamics Simulation; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2023 |
Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling.
Topics: Animals; Fenofibrate; Mice; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Retinal Pigment Epithelium; Signal Transduction; Tumor Necrosis Factor-alpha; Up-Regulation; Vascular Endothelial Growth Factor A | 2023 |